Cord blood transplant after relapse from first transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 0 and 60 years old when you agree to join.
- Your blood cancer must have come back more than 100 days after your first stem cell transplant.
- You can have acute leukemia, myelodysplastic syndrome, or CMML, and your cancer must be in remission (less than 5% blasts in the bone marrow) or your marrow may be low in cells.
- You must have had one previous donor stem cell transplant.
- Your performance status (ability to do daily activities) must be at least 70% on the Karnofsky or Lansky scale.
- Your kidneys, liver, lungs, and heart must be working well enough based on standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.